Parkside Advisors LLC Buys 735 Shares of Johnson & Johnson (NYSE:JNJ)

Parkside Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 23.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,879 shares of the company’s stock after purchasing an additional 735 shares during the period. Parkside Advisors LLC’s holdings in Johnson & Johnson were worth $685,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Price T Rowe Associates Inc. MD lifted its holdings in shares of Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after acquiring an additional 3,912,430 shares during the last quarter. FMR LLC lifted its holdings in shares of Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after acquiring an additional 3,229,032 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after acquiring an additional 2,815,655 shares during the last quarter. GQG Partners LLC lifted its holdings in shares of Johnson & Johnson by 64.4% in the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after acquiring an additional 2,547,378 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Johnson & Johnson by 52.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after acquiring an additional 2,093,392 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. SVB Leerink reduced their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating on the stock. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.

Johnson & Johnson Trading Down 1.1 %

NYSE:JNJ opened at $152.38 on Friday. The firm has a 50 day moving average of $161.97 and a 200 day moving average of $167.88. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 52 week low of $150.71 and a 52 week high of $186.69. The stock has a market capitalization of $396.84 billion, a price-to-earnings ratio of 22.61, a PEG ratio of 2.65 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the business posted $2.13 earnings per share. The firm’s revenue was down 4.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is currently 67.06%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.